相似文献
1
Imaging of tumor angiogenesis: functional or targeted?
AJR Am J Roentgenol. 2009 Aug;193(2):304-13. doi: 10.2214/AJR.09.2869.
2
Imaging of Tumor Angiogenesis for Radiologists--Part 1: Biological and Technical Basis.
Curr Probl Diagn Radiol. 2015 Sep-Oct;44(5):407-24. doi: 10.1067/j.cpradiol.2015.02.010. Epub 2015 Mar 6.
3
Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours.
Br J Radiol. 2011 Dec;84 Spec No 2(Spec Iss 2):S127-44. doi: 10.1259/bjr/66316279.
4
Imaging of angiogenesis: clinical techniques and novel imaging methods.
AJR Am J Roentgenol. 2007 Jan;188(1):11-23. doi: 10.2214/AJR.06.0280.
5
Imaging tumour angiogenesis.
Cancer Imaging. 2005 Dec 1;5(1):131-8. doi: 10.1102/1470-7330.2005.0106.
6
Tumor blood vessel visualization.
Int J Dev Biol. 2011;55(4-5):535-46. doi: 10.1387/ijdb.103229jm.
7
Non-invasive imaging for studying anti-angiogenic therapy effects.
Thromb Haemost. 2013 Mar;109(3):375-90. doi: 10.1160/TH12-10-0721. Epub 2013 Feb 14.
8
Non-invasive assessment of tumor neovasculature: techniques and clinical applications.
Cancer Metastasis Rev. 2008 Dec;27(4):615-30. doi: 10.1007/s10555-008-9147-6.
9
Multimodality molecular imaging of tumor angiogenesis.
J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S. doi: 10.2967/jnumed.107.045922.
10
The role of functional imaging in colorectal cancer.
AJR Am J Roentgenol. 2010 Jul;195(1):54-66. doi: 10.2214/AJR.10.4422.
引用本文的文献
1
Decoding Tumor Angiogenesis for Therapeutic Advancements: Mechanistic Insights.
Biomedicines. 2024 Apr 9;12(4):827. doi: 10.3390/biomedicines12040827.
2
Vascular phenotyping of the invasive front in breast cancer using a 3D angiogenesis atlas.
Microvasc Res. 2023 Sep;149:104555. doi: 10.1016/j.mvr.2023.104555. Epub 2023 May 29.
3
Imaging of Bladder Cancer: Standard Applications and Future Trends.
Medicina (Kaunas). 2021 Mar 1;57(3):220. doi: 10.3390/medicina57030220.
4
Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross-disciplinary translational hypothesis.
FASEB J. 2020 Nov;34(11):14150-14159. doi: 10.1096/fj.202001466R. Epub 2020 Sep 13.
5
Use of 3-D Contrast-Enhanced Ultrasound to Evaluate Tumor Microvasculature After Nanoparticle-Mediated Modulation.
Ultrasound Med Biol. 2020 Feb;46(2):369-376. doi: 10.1016/j.ultrasmedbio.2019.09.019. Epub 2019 Nov 4.
6
Hepatocellular carcinoma treatment: hurdles, advances and prospects.
Hepat Oncol. 2018 Sep 28;5(2):HEP08. doi: 10.2217/hep-2018-0002. eCollection 2018 Apr.
7
The Distribution Volume of F-Albumin as a Potential Biomarker of Antiangiogenic Treatment Efficacy.
Cancer Biother Radiopharm. 2019 May;34(4):238-244. doi: 10.1089/cbr.2018.2656. Epub 2019 Feb 15.
8
Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers.
J Clin Invest. 2019 Feb 1;129(2):442-451. doi: 10.1172/JCI120855. Epub 2019 Jan 7.
9
Functional magnetic resonance imaging of head and neck cancer: Performance and potential.
Neuroradiol J. 2019 Feb;32(1):36-52. doi: 10.1177/1971400918808546. Epub 2018 Nov 6.
10
Grading of pancreatic neuroendocrine neoplasms using pharmacokinetic parameters derived from dynamic contrast-enhanced MRI.
Oncol Lett. 2018 Jun;15(6):8349-8356. doi: 10.3892/ol.2018.8384. Epub 2018 Mar 29.
本文引用的文献
1
New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature.
Eur J Radiol. 2009 Jan;69(1):14-23. doi: 10.1016/j.ejrad.2008.07.037. Epub 2008 Oct 31.
2
Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study.
Ultrasound Med Biol. 2009 Feb;35(2):175-85. doi: 10.1016/j.ultrasmedbio.2008.08.008. Epub 2008 Oct 8.
3
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles.
J Nucl Med. 2008 Aug;49(8):1371-9. doi: 10.2967/jnumed.108.051243. Epub 2008 Jul 16.
4
Anti-VEGF therapy: the search for clinical biomarkers.
Expert Rev Mol Diagn. 2008 May;8(3):301-14. doi: 10.1586/14737159.8.3.301.
5
Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression.
BMC Cancer. 2008 Jun 30;8:186. doi: 10.1186/1471-2407-8-186.
6
Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization.
Acad Radiol. 2008 Jul;15(7):919-27. doi: 10.1016/j.acra.2008.02.005.
7
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
AJR Am J Roentgenol. 2008 Jul;191(1):133-9. doi: 10.2214/AJR.07.2848.
8
Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
J Ultrasound Med. 2008 Jun;27(6):855-66. doi: 10.7863/jum.2008.27.6.855.
9
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients.
J Nucl Med. 2008 Jun;49(6):879-86. doi: 10.2967/jnumed.107.049452. Epub 2008 May 15.
10
68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression.
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1507-15. doi: 10.1007/s00259-008-0757-6. Epub 2008 Mar 28.
Zotero 插件